Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cervical fusion & disc arthroplasty cases in Iowa: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (210 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 9 | 358 | 24% |
| 2020 | 4 | 321 | 27% |
| 2021 | 8 | 408 | 30% |
| 2022 | 9 | 401 | 34% |
| 2023 | 7 | 339 | 38% |
| 2024 | 9 | 408 | 40% |
| 2025 from claims | – | 417 337–490 | 41% |
| 2026 forecast | – | 439 344–551 | 40% |
| 2027 forecast | – | 453 336–599 | 40% |
| 2028 forecast | – | 468 331–645 | 41% |
| 2029 forecast | – | 483 328–692 | 41% |
| 2030 forecast | – | 498 326–739 | 42% |
ACDF, posterior cervical fusion, cervical total disc replacement. Professional codes (what the surgeon bills): CPT 22551, 22600, 22856; the hospital bills MS-DRG 471, 472, 473, 429, 430.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Iowa; 7 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 58% inpatient hospital, 39% hospital outpatient, 3% surgery center. The share outside the hospital has moved +3 pts since 2019, so more of this market is decided in surgery centers and offices each year.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Ohio | 25 | 1,738−4.6%/yr | −4.6%/yr | 1.5 | 5% | 1,920 in 2030+1.7%/yr |
| Illinois | 28 | 1,515−7.1%/yr | −7.1%/yr | 1.1 | 2% | 1,670 in 2030+1.6%/yr |
| Michigan | 24 | 1,338−6.2%/yr | −6.2%/yr | 1.5 | 3% | 1,110 in 2030−3%/yr |
| Missouri | 25 | 1,166−5.8%/yr | −5.8%/yr | 1.8 | 1% | 1,250 in 2030+1.1%/yr |
| Indiana | 21 | 997−4.8%/yr | −4.8%/yr | 1.4 | 3% | 960 in 2030−0.6%/yr |
| Minnesota | 9 | 723−4.6%/yr | −4.6%/yr | 1.5 | 0% | 840 in 2030+2.4%/yr |
| Kansas | 11 | 616−1.8%/yr | −1.8%/yr | 1.5 | 0% | 710 in 2030+2.5%/yr |
| Wisconsin | 3 | 479−5.3%/yr | −5.3%/yr | 0.8 | 4% | 730 in 2030+7.3%/yr |
| Nebraska | 8 | 406−2.1%/yr | −2.1%/yr | 1.5 | 6% | 480 in 2030+2.7%/yr |
| South Dakota | 4 | 201−1.4%/yr | −1.4%/yr | 1.5 | 0% | 270 in 2030+4.8%/yr |
| North Dakota | 3 | 152−5.1%/yr | −5.1%/yr | 1.5 | 0% | 160 in 2030+0.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 23 | 1,138−4.2%/yr | −4.2%/yr | 2.50.8× | 7% | 1,050 in 2030−1.3%/yr |
| Lumbar fusion | 25 | 1,087+7%/yr | +7%/yr | 2.40.9× | 0% | 1,670 in 2030+7.4%/yr |
| Kyphoplasty & vertebroplasty | 2 | 213−11%/yr | −11%/yr | 0.50.3× | 0% | 130 in 2030−7.9%/yr |
Cervical fusion & disc arthroplasty in every state, and its device makers · Every procedure market in Iowa · Every state · Compare with Ohio
Carlsmed leads with 66% of company spending on these surgeons in 2025, +56 pts on 2024.
In 2025, 9 companies reported engagement with Iowa’s surgeons worth $77K in consulting, speaking, meals and travel tied to these products, about $8,512 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 69 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.